TrialAdvances in therapy2026

Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.

Zaihua Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.